筛查结肠镜发现高风险腺瘤仍可预测未来高风险腺瘤,即使中间有一次阴性结肠镜
在美国退伍军人前瞻性筛查结肠镜队列中,891名接受3次及以上结肠镜的参与者中,第三次检查发现高风险腺瘤(HRA)114例(12.8%)。前两次检查均有HRA者第三次HRA发生率最高(14/56,25.0%)。首次检查有HRA者在第二次阴性后第3、5、7年第三次检查HRA风险仍显著升高(OR分别为3.41、3.14、2.89)。
要点
- 前两次检查均发现HRA者第三次检查HRA发生率最高,为25.0%(14/56)。
- 首次有HRA且第二次阴性者,第3年第三次检查HRA风险仍升高(OR 3.41,95%CI 1.28-9.08)。
- 该发现支持现行结直肠癌监测指南关于第二次阴性后缩短至5年行第三次结肠镜的建议。
核心结论
- 在筛查人群中,首次检查发现HRA的个体在第三次检查时仍处于HRA风险升高状态,即使第二次检查为阴性。
- 该发现支持现行结直肠癌监测指南,即基线检查有高风险发现且第二次检查阴性后,建议缩短至5年间隔行第三次结肠镜。
研究设计与样本
- 研究为美国退伍军人前瞻性筛查结肠镜队列(CSP#380)分析。
- 纳入至少接受3次结肠镜的参与者,共891人。
- 采用多变量逻辑回归调整多个协变量。
主要发现
- 第三次检查发现HRA者114例,占891人的12.8%。
- 前两次检查均有HRA者第三次检查HRA发生率最高,为14/56(25.0%)。
- 与两次检查均无腺瘤者相比,首次检查有HRA者在第二次阴性后第3年第三次检查HRA风险显著升高(OR 3.41,95%CI 1.28-9.08)。
- 首次检查有HRA者在第二次阴性后第5年第三次检查HRA风险显著升高(OR 3.14,95%CI 1.49-6.61)。
- 首次检查有HRA者在第二次阴性后第7年第三次检查HRA风险显著升高(OR 2.89,95%CI 1.08-7.74)。
关键数值与推荐
- 现行结直肠癌监测指南建议:基线检查有高风险发现且第二次检查阴性后,第三次结肠镜间隔缩短至5年。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Limited data inform the current postpolypectomy surveillance guidelines, which suggest a shortened interval to third colonoscopy after a negative second examination if high-risk adenomas (HRA) were present on the initial screening colonoscopy. Therefore, we examined the risk of HRA at third colonoscopy stratified by findings on 2 previous examinations in a prospective screening colonoscopy cohort of US veterans. METHODS: We identified participants who had 3 or more colonoscopies from CSP#380. We examined the risk of HRA on the third examination based on findings from the previous 2 examinations. Multivariate logistic regression was used to adjust for multiple covariates. RESULTS: HRA were found at the third examination in 114 (12.8%) of 891 participants. Those with HRA on both previous examinations had the greatest incidence of HRA at third examination (14/56, 25.0%). Compared with those with no adenomas on both previous examinations, participants with HRA on the first examination remained at significantly increased risk for HRA at the third examination at 3 years after a negative second examination (odds ratio [OR] 3.41, 95% confidence interval [CI] 1.28-9.08), 5 years (OR 3.14, 95% CI 1.49-6.61), and 7 years (OR 2.89, 95% CI 1.08-7.74). DISCUSSION: In a screening population, HRA on the first examination identified individuals who remained at increased risk for HRA at the third examination, even after a negative second examination. This finding supports current colorectal cancer surveillance guidelines, which suggest a shortened, 5-year time interval to third colonoscopy after a negative second examination if high-risk findings were present on the baseline examination.
引用
- Sullivan BA, Redding TS, Hauser ER, et al. High-Risk Adenomas at Screening Colonoscopy Remain Predictive of Future High-Risk Adenomas Despite an Intervening Negative Colonoscopy. Am J Gastroenterol. 2020. PMID: 32483010. doi:10.14309/ajg.0000000000000677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。